Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 6/20 | 0.46 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7695561 | 0.81 | ADORA3 (0.52) | ADORA3ADORA2AADORA2BADORA1NPC1 | |
| SCHEMBL9867067 | 0.81 | ADORA3 (0.56) | ADORA3ADORA2AADORA2BADORA1NPC1 | |
| SCHEMBL7214866 | 0.80 | ADORA3 (0.50) | ADORA3ADORA2AADORA2BADORA1NPC1 | |
| SCHEMBL7513501 | 0.76 | ADORA3 (0.46) | ADORA3ADORA2AADORA2BADORA1NPC1 | |
| SCHEMBL7697006 | 0.74 | ADORA3 (0.44) | ADORA3ADORA2AADORA2BADORA1NPC1 | |
| SCHEMBL8075141 | 0.74 | ADORA3 (0.50) | ADORA3ADORA2AADORA2BADORA1MEN1 | |
| SCHEMBL27622712 | 0.73 | ADORA3 (0.42) | ADORA3ADORA2AADORA2BADORA1NPC1 | |
| SCHEMBL930343 | 0.72 | ADORA3 (0.59) | ADORA3ADORA2AADORA2BADORA1NPC1 | |
| SCHEMBL5018849 | 0.72 | ADORA3 (0.53) | ADORA3ADORA2AADORA2BADORA1NPC1 | |
| SCHEMBL14755635 | 0.72 | ADORA3 (0.48) | ADORA3ADORA2AADORA2BADORA1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643299-B1 | BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS | NOSCIRA SA (ES) | 2016-06-22 | — | — | EP | disclosed |
| EP-1121349-B1 | SUBSTITUTED THIADIAZOLSULFONAMIDES USED AS INTERLEUKIN-1-BETA INHIBITORS | AVENTIS PHARMA GMBH (DE) | 2004-03-31 | — | — | EP | disclosed |
| US-6503934-B2 | Suitable for prophylaxis of diseases involving interleukin-1 beta such as septic shock, leukemia, hepatits, muscular degeneration, HIV infections, or degenerative joint diseases | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-01-07 | — | — | US | disclosed |
| US-20010039350-A1 | Substituted thiadiazolesulfonamides | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2001-11-08 | — | — | US | disclosed |
| US-6218412-B1 | THERAPY AND PROPHYLAXIS OF DISEASES WHERE AN INCREASED CONCENTRATION OF INTERLEUKIN-1.BETA. PARTICIPATES IN THEIR COURSE, FOR EXAMPLE SEPTIC SHOCK, LEUKEMIA, HEPATITIS, MUSCULAR DEGENERATION, DEGENERATIVE JOINT DISEASES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039350-A1 | Substituted thiadiazolesulfonamides | COL2A1, IL1B, IL1A | ADORA3 3948/4885ADORA2A 2768/4885ADORA2B 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.